|
11,676
|
| 117762 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 119246 |
ACE2
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic activity of ADAM17
|
| 136192 |
TMPRSS2
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic processing to improve SARS-S-driven transduction
|
|
24227843
|
Immunological
SARS-CoV infection
|
|
11,748
|
| 116392 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolysis
|
|
32333398
|
COVID-19
|
|
11,841
|
| 116921 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic cleavage
|
|
32264791
|
COVID-19
SARS-CoV infection
|
|
11,846
|
| 116942 |
DPC 333
|
|
decreases_quantity of
|
ACE2, soluble
|
implicating ADAM17
|
| 116943 |
cellular response to ionomycin
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116944 |
ACE2, soluble
|
|
decreases_activity of
|
viral entry into host cell
|
|
| 116947 |
ACE2, soluble
|
|
interacts (colocalizes) with
|
SARS-CoV S protein
|
|
| 116949 |
12-O-Tetradecanoylphorbol 13-acetate
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116950 |
Endotoxin
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116951 |
IL1B
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116952 |
TNF
|
|
increases_quantity of
|
ACE2, soluble
|
supporting that ADAM17 and ADAM10 regulate ACE2 cleavage
|
| 116956 |
ACE2 ectodomain proteolysis
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 121046 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in primary human airway epithelial cells
|
|
19411314
|
SARS-CoV infection
|
|
11,847
|
| 133579 |
SARS-CoV S protein
|
|
increases_quantity of
|
ACE2, soluble
|
in the supernatant
|
|
18490652
|
SARS-CoV infection
|
|
11,849
|
| 117001 |
Calmodulin inhibitor
|
|
increases_quantity of
|
ACE2, soluble
|
inhibitors of calmodulin increase the release of the ACE2 ectodomain
|
| 143836 |
ACE2 ectodomain proteolysis
|
|
increases_quantity of
|
ACE2, soluble
|
|
|
18070603
|
SARS-CoV infection
|
|
11,899
|
| 117136 |
ACE2, soluble
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in cerebrospinal fluid
|
| 117156 |
hypertension
|
|
increases_activity of
|
ACE2, soluble
|
in cerebrospinal fluid
|
| 117157 |
ACE2, soluble
|
|
decreases_quantity of
|
Angiotensin II
|
in cerebrospinal fluid
|
|
28512108
|
Neurological
SARS-CoV infection
|
|
11,924
|
| 133119 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
|
24332999
|
Endocrine
|
|
12,014
|
| 117709 |
ACE2, soluble
|
NOT |
affects_activity of
|
inflammatory response
|
|
| 117733 |
ACE2, soluble
|
|
increases_activity of
|
systolic dysfunction
|
|
| 117734 |
ACE2, soluble
|
|
increases_activity of
|
heart failure
|
|
|
19700132
|
Cardiovascular disease
|
|
12,015
|
| 117710 |
ACE2, soluble
|
|
affects_activity of
|
heart failure, acute decompensated
|
after treatment
|
|
24054336
|
Cardiovascular disease
|
|
12,207
|
| 119892 |
ACE2, soluble
|
|
interacts (colocalizes) with
|
SARS-CoV-2 S protein
|
|
|
32294179
|
Diabetes mellitus, type II
Insulin resistance
COVID-19
|
|
12,364
|
| 121098 |
ACE2, soluble
|
|
decreases_activity of
|
SARS-CoV S protein
|
concerning the binding of the SARS-CoV spike protein to its receptor
|
| 121099 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
via shedding
|
|
15983030
|
SARS-CoV infection
|
|
14,053
|
| 133078 |
ACE2, soluble
|
|
affects_activity of
|
Cardiovascular disease
|
|
|
33275517
|
Cardiovascular disease
COVID-19
|
|
14,081
|
| 133079 |
sex, male
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma of patients with heart failure
|
| 133138 |
atrial fibrillation
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
|
32388547
|
Cardiovascular disease
COVID-19
|
|
14,082
|
| 133083 |
sex, male
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma of patients with heart failure
|
|
32388565
|
Cardiovascular disease
COVID-19
|
|
14,088
|
| 133124 |
aging
|
|
increases_quantity of
|
ACE2, soluble
|
in serum
|
| 133125 |
sex, male
|
|
increases_quantity of
|
ACE2, soluble
|
in serum
|
|
32410690
|
Endocrine
COVID-19
|
|
14,090
|
| 133134 |
hypertension
|
|
increases_quantity of
|
ACE2, soluble
|
|
|
33117379
|
COVID-19
|
|
14,095
|
| 133192 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in Angiotensin II rich environment
|
| 133197 |
aging
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; of patients with atrial fibrillation
|
| 133198 |
sex, male
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; of patients with atrial fibrillation
|
| 133199 |
Cardiovascular disease
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; of patients with atrial fibrillation
|
| 133209 |
SASR-CoV-2 S protein
|
|
interacts (colocalizes) with
|
ACE2, soluble
|
|
|
33426683
|
COVID-19
|
|
14,097
|
| 133201 |
sex, male
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; of patients with atrial fibrillation
|
| 133204 |
Cardiovascular disease
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; of patients with atrial fibrillation
|
| 133205 |
Diabetes mellitus
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; of patients with atrial fibrillation
|
| 133206 |
aging
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; of patients with atrial fibrillation
|
|
32984892
|
Cardiovascular disease
COVID-19
|
|
14,127
|
| 133495 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
|
33399851
|
Gastrointestinal
COVID-19
|
|
14,129
|
| 133528 |
SARS-CoV-2 S protein
|
|
interacts (colocalizes) with
|
ACE2, soluble
|
|
|
32942285
|
COVID-19
|
|
14,162
|
| 133830 |
hypertension
|
|
increases_activity of
|
ACE2, soluble
|
in cerebrospinal fluid
|
| 133831 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in cerebrospinal fluid
|
|
24014829
|
Neurological
|
|
14,252
|
| 134528 |
membrane protein ectodomain proteolysis
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 134529 |
ACE2, soluble
|
|
increases_quantity of
|
Angiotensin (1-7)
|
in blood
|
| 134530 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 134532 |
TMPRSS2
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 134536 |
ACE2, soluble
|
|
decreases_activity of
|
viral entry into host cell
|
|
|
32669391
|
Diabetes mellitus, type II
Insulin resistance
COVID-19
|
|
14,273
|
| 134692 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
| 134696 |
Angiotensin II
|
|
increases_quantity of
|
ACE2, soluble
|
via AGTR1
|
| 134697 |
hypertension
|
|
increases_quantity of
|
ACE2, soluble
|
|
|
32208987
|
COVID-19
|
|
14,302
|
| 134953 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
|
|
32305401
|
Cardiovascular disease
COVID-19
|
|
14,307
|
| 135073 |
ACE2, soluble
|
|
interacts (colocalizes) with
|
SARS-CoV-2 S protein
|
in HEK293T cells and HK-2 cells
|
| 135074 |
ACE2, soluble
|
|
interacts (colocalizes) with
|
Arg-vasopressin
|
in HEK293T cells and HK-2 cells; only in the presence of SARS-CoV-2 S protein
|
| 135086 |
ACE2, soluble
|
|
increases_activity of
|
endocytosis involved in viral entry into host cell
|
in HK-2 cells
|
| 136426 |
ACE2, soluble
|
|
is_part_of
|
SARS-CoV-2 S-ACE2, soluble complex
|
in HEK293T cells and HK-2 cells
|
| 136428 |
ACE2, soluble
|
|
is_part_of
|
SARS-CoV-2 S-ACE2, soluble-AVP complex
|
in HEK293T cells and HK-2 cells
|
|
33713620
|
Renal
|
|
14,308
|
| 135043 |
ADAM17
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
| 135045 |
systemic inflammation
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
|
33713620
|
COVID-19
|
|
14,310
|
| 135048 |
sex, male
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
| 135051 |
aging
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; age association is more pronounced in women
|
| 135053 |
post-menopause
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; in women
|
| 135056 |
Metabolic syndrome
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma
|
| 135059 |
obese
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; stronger in men compared to women
|
| 135060 |
increased total body fat amount
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; stronger in men compared to women
|
| 135061 |
Insulin resistance
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; stronger in men compared to women
|
| 135062 |
hyperglycemia
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; stronger in men compared to women
|
| 135063 |
increased circulating triglyceride level
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; stronger in men compared to women
|
| 135064 |
CRP
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; stronger in men compared to women
|
| 135065 |
GGT1
|
|
increases_quantity of
|
ACE2, soluble
|
in plasma; stronger in men compared to women
|
|
32698840
|
Endocrine
Metabolic syndrome
|
|
14,431
|
| 136190 |
TMPRSS2
|
|
increases_quantity of
|
ACE2, soluble
|
via proteolytic processing of membrane-bound ACE2
|
|
21068237
|
Endocrine
SARS-CoV infection
|
CIDeRplus